Kowal Investment Group’s Core Laboratories CLB Stock Holding History

Kowal Investment Group’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2	Closed	–	–	275
2021 Q3	$0	Buy	+2	New	+$61	﹤0.01%	927

Other funds holding CLB

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Kowal Investment Group's CLB Position: Q4 2021 in Review

Kowal Investment Group sold out of Core Laboratories (CLB) in Q4 2021, closing a stake of 2 shares.

Kowal Investment Group first reported a position in CLB in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 174 funds tracked by Wall St. Rank hold CLB as of Q4 2021.

Kowal Investment Group reported no remaining Core Laboratories position as of Q4 2021 after selling out during the quarter.
Kowal Investment Group sold 2 Core Laboratories shares in Q4 2021.
Kowal Investment Group first reported a position in Core Laboratories in Q3 2021 and held it in 1 quarter.
Kowal Investment Group's Core Laboratories position peaked at $0 in Q3 2021.
174 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.